Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 8:59 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 3,262 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo first Clear all

Conditions: Idiopathic Pulmonary Fibrosis, Cough
Interventions: Thalidomide, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 50 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Post Traumatic Stress Disorder (PTSD)
Interventions: SYN117 (nepicastat), Placebo comparator; Drug
Lead sponsor: Michael E. DeBakey VA Medical Center; Federal
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 3
States / cities: Tuscaloosa, Alabama • Charleston, South Carolina • Houston, Texas

Conditions: Pulmonary Arterial Hypertension
Interventions: Carvedilol, Placebo; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Pediatric Pulmonary Hypertension
Interventions: Mono-Therapy with Sildenafil, Duo-Therapy with Sildenafil + Bosentan; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 3 Months to 18 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 10
States / cities: Aurora, Colorado • St. Petersburg, Florida • Baltimore, Maryland + 7 more

Conditions: Sleep Deprivation
Interventions: Sleep Deprivation, Heart Rate, Sleep Monitoring, Diet, Exercise Performance, Surveys, McGill Pain Questionnaire, Shortened Profile of Mood States, Pittsburg Sleep Index, Cognitive performance, Marksmanship Performance, Quick Board, Advanced Medical Technologies Inc, Jump Test, CGM/CKM, Blood Draw, Ketone Supplement; Other · Behavioral · Biological + 1 more
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 40 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Cervical Dystonia
Interventions: Zinc citrate, Placebo; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 89 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Post-operative Ileus
Interventions: Nicotine gum, Regular chewing gum; Drug · Other
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 85 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Weston, Florida

Conditions: Primary Graft Dysfunction, Lung Transplantation, Acute Lung Injury(ALI), Natural Killer Cell Mediated Immunity
Interventions: Maraviroc, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Middle East Respiratory Syndrome Coronavirus
Interventions: SAB-301, Normal (9%) Saline; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: PTSD - Post Traumatic Stress Disorder
Interventions: PT150, Placebo; Drug
Lead sponsor: San Diego Veterans Healthcare System; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: San Diego, California • Houston, Texas

Conditions: Cannabis, Pain, Tolerance, Hyperalgesia
Interventions: Active Cannabis, Placebo Cannabis; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 21 Years to 60 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Opioid Use Disorder
Interventions: Naltrexone, Placebo, Buprenorphine; Drug
Lead sponsor: Alkermes, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 9
States / cities: Lauderhill, Florida • Oakland Park, Florida • Winfield, Illinois + 6 more

Conditions: Surgery, Stress, Pain, Children, Post-Traumatic Stress Disorder
Interventions: Healing Touch, Healing Touch Sham Treatment; Procedure
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 3 Years to 4 Years
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Asthma
Interventions: GSK3772847, Placebo, Fluticasone propionate/salmeterol, Fluticasone propionate; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 33
States / cities: Birmingham, Alabama • Scottsboro, Alabama • Bakersfield, California + 24 more

Conditions: Alcohol Use Disorder
Interventions: CMND-100; Drug
Lead sponsor: Clearmind Medicine Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: New Haven, Connecticut • Baltimore, Maryland

Conditions: Migraine, With or Without Aura
Interventions: Ubrogepant, Placebo-matching Ubrogepant, Usual Care; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 76 Years
Enrollment: 1,254 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 177
States / cities: Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 137 more

Conditions: Healthy Controls
Interventions: Placebo pills for 14-day intervention, VVZ-2471 for 14-day intervention; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Gastric Cancer, Adenocarcinoma
Interventions: ramucirumab, Placebo, Best Supportive Care (BSC); Biological · Drug · Other
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 355 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 14
States / cities: Bakersfield, California • La Jolla, California • Redlands, California + 11 more

Conditions: Colorectal Neoplasms
Interventions: KD018, Irinotecan, Placebo; Drug
Lead sponsor: Edward Chu, MD; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2018
U.S. locations: 2
States / cities: New Haven, Connecticut • Pittsburgh, Pennsylvania

Conditions: Non-Cystic Acne
Interventions: VitaMedica® Clear Skin Formula capsules, Placebo Capsules; Dietary Supplement · Other
Lead sponsor: Ablon Skin Institute Research Center; Other
Eligibility: 18 Years to 40 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Manhattan Beach, California

Conditions: Autism Spectrum Disorder, Aggression, Irritability
Interventions: Transdermal nicotine, Transdermal placebo; Drug · Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: COVID-19, Olfactory Disorder, Parosmia
Interventions: Fluvoxamine, Placebo; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Respiratory Distress Syndrome in Premature Infants, Very Low Birth Weight Baby
Interventions: iNO, Nitrogen; Drug · Other
Lead sponsor: University of Oklahoma; Other
Eligibility: 1 Minute to 2 Minutes
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 2
States / cities: Oklahoma City, Oklahoma

Conditions: Cardiovascular Disease, Diabetes Mellitus, Type 2
Interventions: Goodbelly first, Placebo first; Dietary Supplement
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 40 Years to 80 Years
Enrollment: 215 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Search by objective public record fields.

Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis With Thalidomide

Pharmacogenetic Clinical Trial of Nepicastat for Post Traumatic Stress Disorder (PTSD)

Beta-blockers in Pulmonary Arterial Hypertension

Mono vs. Dual Therapy for Pediatric Pulmonary Arterial Hypertension

Strategies to Augment Ketosis: Ketone Conferred Resiliency Against Sleep Restriction

Zinc as an Adjunctive Therapy for Cervical Dystonia

Nicotine Gum Recovery After Colorectal Surgery

This Study is Assessing the Safety and Efficacy of Immune Inhibition as a Treatment to Prevent Primary Graft Dysfunction

Safety, Tolerability, and Pharmacokinetics of SAB-301 in Healthy Adults

Initial Study Sesting Efficacy and Tolerability of PT150 for PTSD in Veterans

Impact of Repeatedly-Administered THC-cannabis on Experimental Pain and Abuse Liability in Humans

Evaluating Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Transitioning From Buprenorphine Maintenance Prior to First Dose of VIVITROL

The Effects of Healing Touch on Post Operative Pediatric Patients

Efficacy and Safety Study of GSK3772847 in Subjects With Moderately Severe Asthma

A First in Human Study of CMND-100 in Healthy and Alcohol Use Disorder (AUD) Subjects

An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine

Safety and Tolerability Study of VVZ-2471 in Healthy Volunteers

Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma

A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer

A Study to Evaluate the Efficacy and Safety of Clear Skin Formula on Mitigating Mild to Moderate Non-cystic Acne

Nicotinic Cholinergic Modulation as a Novel Treatment Strategy for Aggression Associated With Autism

Fluvoxamine to Augment Olfactory Recovery For Long COVID-19 Parosmia

Inhaled Nitric Oxide (iNO) as an Adjunct to Neonatal Resuscitation

Effect of Probiotic Supplementation on Endothelial Function II